Hemab Therapeutics (NASDAQ:COAG) Major Shareholder Ra Capital Management, L.P. Acquires 1,483 Shares of Stock

Posted by Stephan Jacobs on May 12th, 2026

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Get Free Report) major shareholder Ra Capital Management, L.P. bought 1,483 shares of the stock in a transaction on Friday, May 8th. The stock was acquired at an average cost of $24.98 per share, for a total transaction of $37,045.34. Following the acquisition, the insider directly owned 6,325,914 shares in the company, valued at approximately $158,021,331.72. The trade was a 0.02% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

On Monday, May 11th, Ra Capital Management, L.P. bought 39,869 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.81 per share, for a total transaction of $989,149.89.
On Thursday, May 7th, Ra Capital Management, L.P. bought 9,906 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.46 per share, for a total transaction of $242,300.76.
On Wednesday, May 6th, Ra Capital Management, L.P. bought 68,018 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.60 per share, for a total transaction of $1,673,242.80.
On Tuesday, May 5th, Ra Capital Management, L.P. bought 97,411 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $24.63 per share, for a total transaction of $2,399,232.93.
On Monday, May 4th, Ra Capital Management, L.P. bought 2,675,000 shares of Hemab Therapeutics stock. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $48,150,000.00.